Guidelines on nuclear medicine imaging in neuroblastoma
Guidelines on nuclear medicine imaging in neuroblastoma
复制标题
DOI：
10.1007/s00259-018-4070-8
复制
发表时间：
2018-10-01
影响因子：
9.1
通讯作者：
Giammarile, Francesco
中科院分区：
文献类型：
--
作者：
Bar-Sever, Zvi;Biassoni, Lorenzo;Giammarile, Francesco
核医学在神经母细胞瘤的诊断、分期、反应评估和长期随访中起着核心作用，神经母细胞瘤是儿童最常见的颅外实体肿瘤。这些EANM指南包括关于I-123-mIBG的更新信息，这是核医学中用于评估神经母细胞瘤的最常见研究，以及关于F-18-FDG，F-18-DOPA和Ga-68-DOTA肽的PET/CT成像。这些PET/CT研究越来越多地用于临床实践。适应症，优点和局限性，提出了沿着与研究方案，结果的解释和报告结果的建议。
Nuclear medicine has a central role in the diagnosis, staging, response assessment and long-term follow-up of neuroblastoma, the most common solid extracranial tumour in children. These EANM guidelines include updated information on I-123-mIBG, the most common study in nuclear medicine for the evaluation of neuroblastoma, and on PET/CT imaging with F-18-FDG, F-18-DOPA and Ga-68-DOTA peptides. These PET/CT studies are increasingly employed in clinical practice. Indications, advantages and limitations are presented along with recommendations on study protocols, interpretation of findings and reporting results.